Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms SUNFLOWER
- Sponsors AstraZeneca
Most Recent Events
- 02 Mar 2026 New trial record